Thyroid carcinoma
|
0.500 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Thyroid carcinoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.
|
9140396 |
1997 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have shown that germline mutations of PTEN are present in individuals with two hamartoma syndromes: Cowden Syndrome, associated with a predisposition to breast and thyroid cancers, and Bannayan-Zonana syndrome.
|
9620558 |
1998 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN, encoding a dual-specificity phosphatase on 10q23.3, cause Cowden syndrome (CS), which is characterized by a high risk of breast and thyroid cancers.
|
10514407 |
1999 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations have been implicated in the development of a variety of human neoplasia, including high-grade glioblastoma, prostate, breast, endometrial, and thyroid carcinoma.
|
10910075 |
2000 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we confirm that PTEN mutations in sporadic thyroid cancer are infrequent as we found one point mutation and one heterozygous deletion of PTEN gene in 26 tumors and eight cell lines screened.
|
10918569 |
2000 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN cause Cowden syndrome (CS), which is characterized by multiple hamartomas and a high risk of breast and thyroid cancers.
|
11021816 |
2000 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results suggest that downregulation of PTEN expression at the mRNA level plays a role in PTEN inactivation in thyroid cancer and PTEN exerts its tumour-suppressive effect on thyroid cancer through the inhibition of cell cycle progression alone or both cell cycle progression and cell death.
|
11159944 |
2001 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Whereas PTEN inactivation is uncommon in sporadic thyroid cancer, activation of growth factor pathways that signal through Akt is frequently identified.
|
11507060 |
2001 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors.
|
12203792 |
2002 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We believe this to be the first demonstration of LAR overexpression in thyroid carcinoma and may help to elucidate the role of PTPases in the development of malignancy.
|
12698188 |
2003 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Moreover, germline mutation of PTEN leads to the development of the related hereditary cancer predisposition syndromes, Cowden disease, and Bannayan-Zonana syndrome, wherein breast and thyroid cancer incidence is elevated.
|
15254063 |
2004 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, our results suggest that PTEN can function as an important modulator of extracellular matrix proteins in thyroid cancer.
|
15707585 |
2005 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness.
|
15890670 |
2005 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN, a dual-phosphatase tumor suppressor, is inactivated in Cowden syndrome (CS), characterized by high risk of breast and thyroid cancer, and in variety of sporadic cancers.
|
16436456 |
2006 |
Thyroid carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
PTEN promoter methylation in sporadic thyroid carcinomas.
|
16487009 |
2006 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline PTEN mutations cause 85% of Cowden syndrome (CS), characterized by a high risk of breast and thyroid cancers, and 65% of Bannayan-Riley-Ruvalcaba syndrome (BRRS), characterized by lipomatosis, hemangiomas and speckled penis.
|
17405772 |
2007 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We show here that adenosine triphosphate (ATP) regulates PTEN subcellular localization in a variety of different cancer cell lines, including those derived from breast, colon and thyroid carcinomas.
|
18579579 |
2008 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Because in most of the thyroid carcinomas, DeltaNp73alpha is upregulated, whereas PTEN expression down regulated, we investigated whether DeltaNp73alpha may influence PTEN expression in this cell model.
|
19173293 |
2009 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-beta-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities.
|
19907326 |
2010 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline phosphatase and tensin homolog (PTEN) mutations cause Cowden syndrome (CS), associated with breast and thyroid cancers.
|
20600018 |
2010 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Children presenting with thyroid cancer should be tested for PTEN mutations.
|
21956414 |
2011 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Notably, individuals with SDH(var+) alone had the highest thyroid cancer prevalence (24/47) compared with PTEN(mut+) patients (27/105, P = 0.002) or PTEN(mut+)/SDH(var+) carriers (6/22, P = 0.038).
|
21979946 |
2012 |